unknown
Stage
2025
Founded
4
Investors
About
Arthex Biotech develops RNA-based medicines focused on anti-miR therapies targeting diseases with unmet medical needs, including their lead program for Myotonic Dystrophy.
Explore Arthex Biotech's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.